Author Archives: Steve Bryson PhD

Enrollment Resumes in GALACTIC-1 Trial of Inhaled Therapy GB0139

Enrollment has resumed, under a revised trial protocol, in the Phase 2b study GALACTIC-1, which is evaluating Galecto’s investigational inhaled therapy GB0139 in adults with idiopathic pulmonary fibrosis (IPF). Galecto in March had been advised to stop recruiting and treating certain trial participants after disparities were…

Computer Analysis IDs New IPF-halting Therapeutic Target

A computer analysis identified a tiny RNA molecule, or microRNA, as a potential therapeutic target to halt the progression of idiopathic pulmonary fibrosis (IPF), which was confirmed later in cell-based tests. Researchers now plan to use these results to develop new RNA-based therapeutics or small molecules with the potential…

FDA Accepts Priority Review Request for Tyvaso DPI

The U.S. Food and Drug Administration (FDA) has accepted United Therapeutics’ application for a priority review of Tyvaso DPI, an experimental dry powder inhaled formulation of treprostinil, to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). …

Microgel-coated Cells Reverse Established PF in Mice

Scientists found that mesenchymal stromal cells (MSCs) — cells that have similar properties to stem cells — individually coated with a soft microgel were able to reverse established lung tissue scarring in a mouse model of pulmonary fibrosis.  Their findings were reported in…

Smoking, Oxygen Use Linked to Higher Hospitalization Risk in IPF

While receiving treatment at specialized centers lowers the risk of hospitalization among patients with idiopathic pulmonary fibrosis (IPF), being a former smoker and requiring oxygen therapy are both associated with a higher likelihood of hospitalization. These are some of the findings of multiple studies that Boehringer Ingelheim will…